Abstract
We conducted a clinical study on malignant tumors other than squamous cell carcinomas developing from the oral and maxillofacial region. We examined a total of 93 patients who visited our hospital for treatment over a 10-year period （2006-2015）, and who had been diagnosed with salivary gland cancer （81 patients）, osteosarcoma （four patients）, soft tissue sarcoma （four patients）, and/or primary mucosal malignant melanoma （four patients）. This patient cohort comprised 5.3％ of the 1,753 patients who visited our hospital for treatment of malignant tumors during this period, apart from 68 patients who were diagnosed with malignant lymphoma. In cases of salivary gland cancers, the accurate assignment of safety margins, with respect to the observed histologic malignancy, is important; the disease-specific 10-year cumulative survival rate of patients who underwent pathological stump resections decreased to 69.1％. In cases of bone and soft tissue tumors, administration of pre – and postoperative chemotherapy, and resection using wider margins decreased mortality rates （except for one patient）, and improved favorable results. In patients with primary mucosal malignant melanomas, it was necessary to perform an extensive resection and neck dissection within the appropriate range and administer postoperative adjuvant chemotherapy. One patient experienced tumor-bearing survival without death due to the disease, and follow-up was continued for six years postoperatively. Patient survival time is expected to improve further through the application of immunotherapy, which has rapidly progressed in recent years. The disease-specific 5-year and 10-year cumulative overall survival rates of the 93 patients were 93.7％ and 81.4％, respectively. In patients with tumors of specialized tissue types, favorable resection results can be obtained by using the appropriate resection range and relevant adjuvant therapy.
